Rheumatologists can act as advocates for patients and their families in a way that supports targeting vasculitis early. Here’s how…

Subcategories:Axial SpondyloarthritisGout and Crystalline ArthritisGuidelinesMyositisOsteoarthritis and Bone DisordersOther Rheumatic ConditionsPain SyndromesPediatric ConditionsPsoriatic ArthritisRheumatoid ArthritisSjögren’s DiseaseSoft Tissue PainSystemic Lupus ErythematosusSystemic SclerosisVasculitis
Rheumatologists can act as advocates for patients and their families in a way that supports targeting vasculitis early. Here’s how…
New research explores the genome-wide epigenetic changes associated with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). The results suggest distinct patterns in DNA methylation may become a useful diagnostic marker…
Clinicians and researcher are gaining tools and insights into SLE, with newly proposed classification criteria and new findings on SLE pathogenesis presented at the 2018 EULAR: Annual European Congress of Rheumatology…
New research into neurosarcoidosis suggests certain clinical and imaging features are indicative of a more aggressive neurological disease. The study provides insight into the clinical features of neurosarcoidosis, as well as the relationship between neurological involvement and systemic disease…
Lisa Rapaport |
(Reuters Health)—Art museums may have an analgesic effect on chronic pain, a small study suggests. Chronic pain sufferers who took guided tours of art museums felt less discomfort and unpleasantness related to their pain shortly afterward, researchers found. The researchers invited 54 visitors to the Crocker Art Museum in Sacramento, Calif., who reported experiencing chronic…
Lorraine L. Janeczko |
NEW YORK (Reuters Health)—In patients with active non-radiographic axial spondyloarthritis (nr-axSpA) who achieved remission while taking adalimumab, researchers saw fewer flares among those who continued taking the drug than among those who stopped taking it. “The results showed that continued therapy with adalimumab was associated with a higher rate of maintenance of remission compared with…
While African Americans and Hispanics—especially women in these ethnic groups—are disproportionately affected by lupus, they are under-represented in clinical trials in lupus and other chronic diseases.1,2 With the help of a new federal grant, the ACR took the first step to address this lack of diversity in lupus trials this year. The ACR’s Collaboration Initiatives…
AMSTERDAM—Molecular signatures in synovial tissue that can be gathered through biopsies are a largely untapped resource that could help guide treatment for rheumatic conditions, an expert said at the EULAR: Annual European Congress of Rheumatology. “I’m convinced that looking into synovial tissue provides us with tools to not only understand mechanisms of disease in rheumatoid…
Catherine Kolonko |
Researchers in Demark studied joints of young adult athletes to better understand the difference in bone marrow edema common in healthy people vs. what is experienced by patients with spondyloarthritis, a serious inflammatory condition of the spine and sacroiliac joints. Early recognition of spondylo-arthritis can be tricky because it can be confused with symptoms and…
A new biologic agent for treatment of systemic lupus erythematosus (SLE) being tested in clinical trials is showing promise as a safe and effective new treatment, particularly in patients with more severe disease or serologically active disease. Recently published results of a study that examined the safety and efficacy of atacicept for SLE showed the…